Akers Biosciences Share Discussion Threads

[algernon2] 12/2/2015 16:30

One hopes they will like the T.A.R.D.I.S. Materialise to save us when least expected Norbus.

[algernon2] 11/2/2015 23:37

Courtesy of Proactiveinvestors:
February 9th.

"Akers Biosciences receives stamp of approval from certification body

Medical device company Akers Biosciences (LON:AKR) has passed a significant milestone with the award of ISO certification for its management system.

The system has been certified by SAI Global, a leading global management systems certification body, to ISO 13485.

ISO 13485 is an International Organization for Standardization (ISO) standard, published in 2003, that represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices.

It may not sound that exciting but the certification is a requirement in certain countries to enable regulatory approval of medical devices, so it represents, in the words of executive chairman Raymond Akers, a "vital step" in Akers's expansion programme.

"As well as demonstrating to future potential partners and distributors the company's commitment to a quality management system, it may also help accelerate the process of gaining regulatory clearance for medical devices in certain countries, allowing us to get products to market faster," Dr Akers observed.

It is the second bit of good news the company has received on the regulatory front this year; last month it revealed it now has European patent protection for its blood separator and the methods it employs to split fluids from whole blood."

[craigo3] 06/2/2015 07:54

Get into Halosource you might start seeing your money grow.

[craigo3] 06/2/2015 07:52

I got out of these a long time ago, glad I did theres no hope for this hopeless lot, what you are seeing is the very slow death of the company.

[mcmather] 06/2/2015 07:34

Dr Dollar is a canny operator. He also said "This activity, combined with a good pipeline of new products, should provide a strong platform for future growth".

On 10 September 2003.....

[rivaldo] 06/2/2015 07:20

The CEO's getting out and about, presenting in New York next week:



"Fri, Feb 6, 2015, 2:17 AM EST
Akers Presenting at US Investor Conference

Executive Chairman Raymond F. Akers Jr., Ph.D, to Present at the 17th Annual BIO CEO & Investor Conference

THOROFARE, N.J., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (AKER) (AIM:AKR.L), ("Akers" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnosis, announces that its Executive Chairman, Raymond F. Akers Jr., Ph.D, will present to prospective investors next week at the 17th Annual BIO CEO & Investor Conference in New York City.

The BIO CEO & Investor Conference is one of the USA's largest investor conferences focused on publicly traded and select private biotech companies.

"I look forward to meeting prospective investors at the BIO CEO conference next week and discussing how Akers is poised to capitalize on the growth of the in vitro diagnostics market by providing more rapid and easy diagnostic solutions to accelerate clinical decision-making and reduce the cost of healthcare."

The 17th Annual BIO CEO & Investor Conference is being held at the Waldorf Astoria New York on February 9-10, 2015. For more information visit: hxxps://www.bio.org/events/conferences/bio-ceo-investor-conference"

[mcmather] 05/2/2015 15:49

Some concerns re that latest presentation; seems to be the usual smoke and mirrors. Will comment later. In the meantime, and just on the very, very slim chance of the JV with Konica Minolta coming to anything......

[werewolfie] 30/1/2015 23:13

It should be named Rudolph the red nosed reindeer.

[algernon2] 30/1/2015 22:32

Akers Biosciences: Rapid Point of Care Diagnostics with Mass Market Potential



Its new and its showing at a screen near you!

[werewolfie] 29/1/2015 21:17

One more year then im looking to move if there is no real change.

Been in 2 years already. Get Dr Dollar-DoLittle back in the lab where he can blow his hot air into the breathalyzers

[mcmather] 28/1/2015 22:34

Dr Dollar and TDH were seemingly at it a little earlier. No trace yet of the presentation:

[algernon2] 26/1/2015 22:15

Ok thats done: email sent to Dave at Redchip inviting him to the party here on ADVFN and to read last 2 months comments and respond/ask Dr Akers about them.
Mcmather weren't you talking/meeting with Dr Akers in the dim and distant past in London or did I imagine that or did the meeting not go ahead.Vaguely remember that I think.
Maybe we can ask some proxy questions at the next AGM.
I have always meant to go to one for AKR or Oxb or Summ but always found something better to do instead on the day or it was held too early in the morning(usually 10 am for some reason) to get to more likely.
Also the distance to New Jersey is a slight crimping factor in the particular case of AKR.
Can as shareholders we submit questions via a proxy at the AGM and demand they be answered?
All the best.
Algernon2

[algernon2] 26/1/2015 21:26

you may well be right Mcmather; I was being unrealistically hopeful and giving him the benefit of the doubt.
As we realise though, the benefit of the doubt can only be extended so far and Dr Ray needs to step up to the mark rapidly.
i am considering copying Redchip and "Dave Gentry" into my concerns and queries and asking him to give "ray" a more rocky ride next time they "converse".
Just to see Daves reaction to the idea of possibly biting the hand that feeds him will be revealing.
I will of course let you know if I get a reply.

[mcmather] 26/1/2015 20:56

algernon, I have previously gone through every RNS issued by AKR whilst it has been publicly listed and most of which, if not all, have been commented on by or signed off by Dr Raymond Akers Jr. There was a spell around 2010 onwards - and when a few of us were in communication with TAN and complaining about far too giddy statements - when the formal announcements took on a more prosaic approach. Things have reverted to normal from 2014 following TAN being jettisoned.

Notwithstanding the period above, invariably, the statements have been massively giddy in terms how things now are and will be in the next 6 / 12 / 24 months, etc. None of which have ever actually come to fruition - any new business has been short lived and usually limited to a one off contract.

Dr Raymond Akers Jr has continued to receive a remuneration package around the $300k mark pa and regardless as to how pathetic the company have performed, both financially and from a shareholders perspective.

The point I'm trying to make is that I very much doubt, based on my experience here - see above - that Dr Akers gives a tuppenny toss as to what the likes of you, I or the many US investors who subscribed to the nasdaq listing think.

This RNS is procedural stuff; needed re any European sales of PIFA PF4 Pluss and, perhaps, it might also be of assistance if the company subcontract production of any of the devices to outside their US base (the PIFA range)?

Back in 2011 we highlighted on here the potential benefit of licensing the technology out. When Dr Raymond Akers Jr - remember you, as a shareholder, employ him - responds to your email from the other day, ask him why there have been no take ups from other providers / manufacturers since March 2011 when the technology was patented in the US?

Dr Akers has previously stated that the idea is to sell the company - either part, or lock, stock and barrel - in 3-5 years. The funds / current revenue will likely see the company through to that.

If the, ahem, remuneration committee decided to award some key personnel (eg Wistful Walt) with some more shares, Dr Raymond Akers Jr could easily pocket $2m+ prior to any potential sale of the company.

The soon to be released results will allude to increasing shareholder value and statler & waldorf will no doubt be seen in a youtube get together, but I think any realism creeping in might more likely be from us shareholders here in the UK and the US, as opposed from Dr Dollar.

[mcmather] 26/1/2015 09:38

Edwin C. Hendrick
Former Executive Vice President of Sales & Marketing, Akers Biosciences Inc.

[mcmather] 26/1/2015 08:00

It certainly isn't bad news, the caveat being that the below is the respective RNS pertaining to the US patent protection of the same technology 16 March 2011 and that has yet to reap benefits for PIFA PF4 (Pluss) or attract other companies wanting to use the technology under license in the 4 years since:

The Technology could also be used in many other diagnostic tests transforming them from use only in clinical laboratories to point-of-care.

ABI's Technology is for a novel composite which enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. Serum or plasma samples are extracted within minutes and are ready for immediate analysis by rapid assay devices, such as ABI's own products, delivering real-time results. By contrast, conventional methods of blood cell separation are labour-intensive and time consuming, typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialised equipment.

[rivaldo] 26/1/2015 07:33

Nice - European patent granted for AKR:



"European Patent Granted for Akers' Rapid Blood Separation Technology

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that the European Patent Office has issued a patent surrounding the Company's novel blood separator technology and method of separating a fluid fraction from whole blood (the "Technology"). Akers was granted U.S. patent protection for the Technology in 2011.

The Technology, developed and wholly owned by Akers, enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. By utilizing the Technology, serum or plasma samples are extracted within 30-90 seconds and are ready for immediate analysis. By contrast, conventional methods of blood cell separation are labor-intensive and time consuming, taking 30-120 minutes, and typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialized equipment.

The Technology, which further accelerates the rate at which a test result is obtained, is marketed by Akers under the brand name seraSTAT® and forms a key component of the Company's PIFA product range (Akers' proprietary platform for rapidly detecting or measuring specific proteins or other substances through their properties as antigens or antibodies). In addition to seraSTAT®'s incorporation within some of the Company's own diagnostic tests, Akers intends to license its proprietary blood separator Technology to third parties seeking to accelerate their own testing procedures by facilitating the blood cell separation process as a component of their test.

"We believe the Company's blood separator Technology has a wide range of potential applications and we are actively seeking potential commercialization partners and licensees in both Europe and the U.S.," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of the Board.

"This Technology can make blood cell separation dramatically quicker and less resource-intensive than traditional methods - with significant potential advantages related to cost savings, staff efficiency, and the ability to perform certain diagnostic tests in the field versus lab environments," continued Dr. Akers."

[mcmather] 24/1/2015 14:05

23 Jan 2015 - Think this was already known:

ACT Capital Management, LLLP is the beneficial owner of 378,500 shares of common stock of the Issuer or approximately 7.3% of the total number of shares of common stock of the Issuer outstanding. Amir L. Ecker and Carol G. Frankenfield are the General Partners of ACT Capital Management, LLLP. Investment decisions made on behalf of ACT Capital Management, LLLP are made primarily by its General Partners.

[vancoillie] 23/1/2015 14:45

Nice opening in US, ➕ 18%

[mcmather] 23/1/2015 14:08

Speaking of being busy, I am sure that the following trades are entirely unrelated to any Incentive (cough, cough, splutter) Stock and Award Plan:

15:34:30 20-Jan-2015 235.25 5,498 12,934.04 Ordinary Trade - delayed publication request.
11:32:08 23-Jan-2015 220.00 12,000 26,400.00 Ordinary Trade - delayed publication request
11:31:08 23-Jan-2015 220.00 12,000 26,400.00 Ordinary Trade - delayed publication request